Pharma · Private company

Jazz Pharmaceuticals

Track this companyFree. Adds Jazz Pharmaceuticals to your Dealase workspace and tells you when its record changes.

Clinical trials2525 recruiting or active

Pipeline programs29From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline29

CisplatinPhase 3 · Biliary Tract CancerClinicalTrials.gov · fetched Nov 12, 2026
DurvalumabPhase 3 · Biliary Tract CancerClinicalTrials.gov · fetched Nov 12, 2026
GemcitabinePhase 3 · Biliary Tract CancerClinicalTrials.gov · fetched Nov 12, 2026
JZP926 capsulePhase 3 · Juvenile Myoclonic EpilepsyClinicalTrials.gov · fetched Nov 12, 2026
PembrolizumabPhase 3 · Biliary Tract CancerClinicalTrials.gov · fetched Nov 12, 2026
XywavPhase 3 · NarcolepsyClinicalTrials.gov · fetched Nov 12, 2026
ZanidatamabPhase 3 · Biliary Tract CancerClinicalTrials.gov · fetched Nov 12, 2026
CarboplatinPhase 2 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
DocetaxelPhase 2 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
DurvalumabPhase 2 · Extensive-stage Small-cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
JZP3507Phase 2 · MeningiomaClinicalTrials.gov · fetched Nov 12, 2026
LurbinectedinPhase 2 · Refractory Ewing SarcomaClinicalTrials.gov · fetched Nov 12, 2026
LurbinectedinPhase 2 · Extensive-stage Small-cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
ONC206Phase 2 · Advanced Pheochromocytoma and ParagangliomaClinicalTrials.gov · fetched Nov 12, 2026
ONC206: Dose 1Phase 2 · Advanced Pheochromocytoma and ParagangliomaClinicalTrials.gov · fetched Nov 12, 2026
ONC206: Dose 2Phase 2 · Advanced Pheochromocytoma and ParagangliomaClinicalTrials.gov · fetched Nov 12, 2026
PaclitaxelPhase 2 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
PertuzumabPhase 2 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
TrastuzumabPhase 2 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
ZanidatamabPhase 2 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
ZanidatamabPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
CBD-OSPhase 1 · Focal SeizuresClinicalTrials.gov · fetched Nov 12, 2026
JZP047Phase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
JZP269Phase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
JZP815Phase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
ONC206Phase 1 · Central Nervous System NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
Cannabidiol Oral SolutionLennox-Gastaut SyndromeClinicalTrials.gov · fetched Nov 12, 2026
EpidiolexMaternal ComplicationsClinicalTrials.gov · fetched Nov 12, 2026
ZanidatamabEsophageal CancerClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)PHASE1 · NOT_YET_RECRUITING · started Apr 1, 2027ClinicalTrials.gov NCT07899801 · fetched Nov 12, 2026
Lurbinectedin With Osimertinib in Transformed Small Cell Lung CancerPHASE1_PHASE2 · RECRUITING · started Jan 1, 2027ClinicalTrials.gov NCT07153055 · fetched Nov 12, 2026
Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEANOT_YET_RECRUITING · started Nov 30, 2026ClinicalTrials.gov NCT07780968 · fetched Nov 12, 2026
A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGSPHASE4 · NOT_YET_RECRUITING · started Nov 18, 2026ClinicalTrials.gov NCT07728097 · fetched Nov 12, 2026
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCPHASE2 · RECRUITING · started Oct 12, 2026ClinicalTrials.gov NCT07459634 · fetched Nov 12, 2026
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female ParticipantsPHASE1 · RECRUITING · started Sep 22, 2026ClinicalTrials.gov NCT07813663 · fetched Nov 12, 2026
A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic EpilepsyPHASE2_PHASE3 · RECRUITING · started Sep 18, 2026ClinicalTrials.gov NCT07723963 · fetched Nov 12, 2026
Epidiolex Trial for Presymptomatic Treatment of Sturge-Weber SyndromePHASE2 · RECRUITING · started Sep 17, 2026ClinicalTrials.gov NCT07778810 · fetched Nov 12, 2026
AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal AdenocarcinomasPHASE2 · RECRUITING · started Jul 20, 2026ClinicalTrials.gov NCT07290985 · fetched Nov 12, 2026
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 MeningiomaPHASE2 · RECRUITING · started Jul 16, 2026ClinicalTrials.gov NCT07533942 · fetched Nov 12, 2026
A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IHPHASE3 · RECRUITING · started Jul 9, 2026ClinicalTrials.gov NCT07625280 · fetched Nov 12, 2026
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy ParticipantsPHASE1 · ACTIVE_NOT_RECRUITING · started Feb 3, 2026ClinicalTrials.gov NCT07377539 · fetched Nov 12, 2026
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and ParagangliomaPHASE2 · RECRUITING · started Jan 2, 2026ClinicalTrials.gov NCT07282587 · fetched Nov 12, 2026
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset SeizuresPHASE1 · RECRUITING · started Nov 26, 2025ClinicalTrials.gov NCT07233239 · fetched Nov 12, 2026
Study of Cannabidiol and Neuroimaging on StressPHASE1_PHASE2 · RECRUITING · started Oct 29, 2025ClinicalTrials.gov NCT07278505 · fetched Nov 12, 2026
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerPHASE2 · RECRUITING · started Sep 24, 2025ClinicalTrials.gov NCT07102381 · fetched Nov 12, 2026
Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During PregnancyRECRUITING · started Aug 5, 2025ClinicalTrials.gov NCT06113237 · fetched Nov 12, 2026
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsPHASE2 · RECRUITING · started Jan 14, 2025ClinicalTrials.gov NCT06695845 · fetched Nov 12, 2026
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerPHASE3 · RECRUITING · started Jul 19, 2024ClinicalTrials.gov NCT06282575 · fetched Nov 12, 2026
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing SarcomaPHASE1_PHASE2 · RECRUITING · started May 23, 2023ClinicalTrials.gov NCT05734066 · fetched Nov 12, 2026
PRE-ISPY Phase I/II Oncology Platform ProgramPHASE1_PHASE2 · RECRUITING · started Feb 15, 2023ClinicalTrials.gov NCT05868226 · fetched Nov 12, 2026
Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid NeoplasmsPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 17, 2023ClinicalTrials.gov NCT05656248 · fetched Nov 12, 2026
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815PHASE1 · ACTIVE_NOT_RECRUITING · started Oct 10, 2022ClinicalTrials.gov NCT05557045 · fetched Nov 12, 2026
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Nov 18, 2021ClinicalTrials.gov NCT05091567 · fetched Nov 12, 2026
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsPHASE1 · ACTIVE_NOT_RECRUITING · started Oct 26, 2020ClinicalTrials.gov NCT04541082 · fetched Nov 12, 2026